Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.43 |
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.38 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9631667 | 1.00 | PARP1 (0.50) | PARP1CES2CES1TAS1R3TAS1R1 | |
| Hydrochloric Acid SCHEMBL30298861 | 0.98 | PARP1 (0.48) | PARP1CES2CES1TAS1R3TAS1R1 | |
| SCHEMBL349820 | 0.84 | PARP1 (0.60) | PARP1TPMTADRA1DMAP4K4HCAR1 | |
| SCHEMBL7077548 | 0.84 | PARP1 (0.60) | PARP1CES2CES1HCAR1CYP3A4 | |
| SCHEMBL259315 | 0.84 | CES2 (0.62) | PARP1CES2CES1HCAR1CYP3A4 | |
| SCHEMBL5048829 | 0.84 | PARP1 (0.60) | PARP1TPMTADRA1DMAP4K4HCAR1 | |
| Hydrochloric Acid SCHEMBL4371939 | 0.81 | PARP1 (0.58) | PARP1TPMTADRA1DMAP4K4HCAR1 | |
| SCHEMBL14310497 | 0.81 | CES1 (0.43) | CES2CES1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5223999 | 0.80 | CES2 (0.46) | CES2CES1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL572200 | 0.80 | TPMT (0.70) | CES2CES1TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606546-B2 | Small molecule inhibitors of calcium channel activity and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4673219-A1 | CRYSTALLINE SALT FORMS OF N-((1-(2-(TERT-BUTYLAMINO)-2-OXOETHYL)PIPERIDIN-4-YL)METHYL)-3-CHLORO-5-FLUOROBENZAMIDE AND METHODS OF USE THEREOF | Praxis Precision Medicines, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4673131-A1 | HIGH STRENGTH SINGLE UNIT DOSE FORMULATIONS AND METHODS OF USE THEREOF | Praxis Precision Medicines, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12486257-B2 | Small molecule inhibitors of CaV3.2 activity and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-12-02 | — | — | US | disclosed |
| WO-2024182654-A1 | HIGH STRENGTH SINGLE UNIT DOSE FORMULATIONS AND METHODS OF USE THEREOF | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| WO-2024182647-A1 | CRYSTALLINE SALT FORMS OF N-((1-(2-(TERT-BUTYLAMINO)-2-OXOETHYL)PIPERIDIN-4-YL)METHYL)-3-CHLORO-5-FLUOROBENZAMIDE AND METHODS OF USE THEREOF | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20230365544-A1 | SMALL MOLECULE INHIBITORS OF CALCIUM CHANNEL ACTIVITY AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH | 2023-11-16 | — | — | US | disclosed |
| CN-116669724-A | T-type calcium channel modulators and methods of use thereof | 普拉西斯精密医药公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230192674-A1 | SMALL MOLECULE INHIBITORS OF CAV3.2 ACTIVITY AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365544-A1 | SMALL MOLECULE INHIBITORS OF CALCIUM CHANNEL ACTIVITY AND USES THEREOF | CACNA1G, CACNA1I, CACNG3 | PARP1 819/4885CES2 693/4885CES1 3852/4885 |
| US-12606546-B2 | Small molecule inhibitors of calcium channel activity and uses thereof | CACNA1G, CACNA1I, CACNA1D | PARP1 646/4885CES2 655/4885CES1 4012/4885 |
| US-12486257-B2 | Small molecule inhibitors of CaV3.2 activity and uses thereof | CACNA1B, CACNG3, CACNA1C | PARP1 1616/4885CES2 570/4885CES1 4546/4885 |
| US-20230192674-A1 | SMALL MOLECULE INHIBITORS OF CAV3.2 ACTIVITY AND USES THEREOF | CACNA1B, CACNG3, CACNA1C | PARP1 1716/4885CES2 570/4885CES1 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.